Ann: Positive Preclinical Data for ARG-007 Neuroprotection in HIE, page-87

hahahaha.... we are way too early for this discussion...

remember we don't even have a P1 data.....in my years of experience not only on ASX but also being part of various Pharmaceutical companies over last 10 plus years.....it all depends on multiple things.....


max valuation I have seen post P2 and a company in P3 with one single asset is approx. 10b..... it was for a gene therapy company fixing a very niche market.....

let's hope the data comes out to be exceptional .... and given what's it's trying to solve.... if there is ever a take over, it will be billions not 1 billion ..

but like I said .... too early, we have a lot of hurdles to go through .... minimum wait in my view is 3-4 years...